• Administer only enterally (e.g., oral, nasogastric tube, or gastric tube route). Do not administer intravenously or by other parenteral routes (2.1)
• Give one hour before a meal or two hours after a meal (2.1)
• Start dosing within 96 hours of the SAH (2.1)
• Recommended dose is 20 mL (60 mg) every 4 hours for 21 consecutive days (2.2)
• Nasogastric or Gastric Tube Administration: Administer 20 mL (60 mg) every 4 hours with supplied oral syringe. Refill syringe with 20 mL of 0.9% saline water solution; flush remaining contents from nasogastric or gastric tube into stomach (2.3)
• Patients with Cirrhosis: Reduce dosage to 10 mL (30 mg) every 4 hours (2.4)

Oral solution: 60 mg per 20 mL (3)
CONTRAINDICATIONS
None (4)
WARNINGS AND PRECAUTIONS

• Hypotension: Monitor blood pressure (5.1)
• Patients with Cirrhosis: Higher risk of adverse reactions. Monitor blood pressure and pulse (5.2)
• CYP3A4 Strong Inhibitors: May significantly increase risk of hypotension. Concomitant use with NYMALIZE should generally be avoided (5.3)
• CYP3A4 Strong Inducers: May significantly reduce efficacy of nimodipine. Concomitant use with NYMALIZE should generally be avoided (5.4)

Most common adverse reactions (incidence ≥1% and ≥1% placebo) were hypotension, headache, nausea, and bradycardia (6)
To report SUSPECTED ADVERSE REACTIONS, contact Arbor Pharmaceuticals, LLC at 1-866-516-4950 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS

• Anti-Hypertensives: May increase risk of hypotension. Monitor blood pressure (7.1)
• CYP3A4 Moderate and Weak Inhibitors: May increase risk of hypotension. Monitor blood pressure. Dose reduction of NYMALIZE may be needed. Avoid grapefruit juice. (7.2)
• CYP3A4 Moderate and Weak Inducers: May reduce efficacy of NYMALIZE. Dose increase may be needed (7.3)

• Pregnancy: Based on animal data may cause fetal harm (8.1)